NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
IGM Biosciences, Inc.
Hospital Universitari de Bellvitge
Bionomics Limited
CR-CSSS Champlain-Charles-Le Moyne
EMD Serono